

Development of Inhaled Antibacterial Treatments for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis; Public Workshop—June 27, 2018

Speakers and Panelists

Timothy Aksamit, MD

Associate Professor of Medicine
Pulmonary Disease and Critical Care Medicine
Mayo Clinic
Rochester, MN

Jeff Alder, PhD

Anti-Infective Consulting, LLC
Margaretville, NY

Maria Allende, MD

Medical Officer
Division of Anti-Infective Products (DAIP),
Office of Antimicrobial Products (OAP), Office of New Drugs (OND)
CDER, FDA, Silver Spring, Maryland

Alan Barker, MD

Professor of Medicine, Division of Pulmonary and Critical Care Medicine
Oregon Health & Science University
Portland, OR

James Chalmers, PhD

Professor
Department of Respiratory Medicine
Ninewells Hospital and Medical School, University of Dundee
British Lung Foundation Chair of Respiratory Research
Dundee, UK

Wen-Hung Chen, PhD

Reviewer
Clinical Outcome Assessment Staff
OND, CDER, FDA, Silver Spring, MD

Edward Cox, MD, MPH

Director
OAP
OND, CDER, FDA, Silver Spring, MD

Rajiv Dhand, MD

Professor and Chairman
Department of Medicine
University of Tennessee Graduate School of Medicine
Knoxville, TN

Susan Ellenberg, PhD

Professor
Biostatistics, Department of Biostatistics and Epidemiology
University of Pennsylvania School of Medicine
Philadelphia, PA

Patrick Flume, MD

Professor
Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Dean Follmann, PhD

Chief
Biostatistics Research Branch
National Institute of Allergy and Infectious Diseases
Bethesda, MD

Juergen Froehlich, MD

Chief Medical Officer
Aradigm Corporation
Hayward, CA

Nicole Hamblett, PhD

Professor, Department of Pediatrics
Adjunct Professor, Department of Biostatistics
University of Washington
Co-Executive Director, Cystic Fibrosis Therapeutics Development Network (CF TDN)
Coordinating Center
Seattle Children's Research Institute
Seattle, WA

Chip Hawkins

Patient Representative- Cystic Fibrosis
Baltimore, MD

Chris Kadoorie, PhD

Statistical Reviewer
Division of Biometrics IV
Office of Biostatistics
Office of Translational Sciences (OTS),
CDER, FDA

Peter Kim, MD

Medical Officer
DAIP, OAP
OND, CDER, FDA, Silver Spring, MD

Deepika Lakhani, PhD

Team Lead
Respiratory and Pulmonary Devices Branch, Office of Device Evaluation
Center for Devices and Radiologic Health, FDA
Silver Spring, MD

Robert Lim, MD

Lead Medical Officer
Division of Pulmonary, Allergy, and
Rheumatology Products
OND, CDER, FDA, Silver Spring, MD

Shrimant Mishra, MD, MPH

Medical Officer
DAIP, OAP
OND, CDER, FDA, Silver Spring, MD

Sumathi Nambiar, MD, MPH

Director
DAIP, OAP
OND, CDER, FDA, Silver Spring, Maryland

Quynh Nguyen, PhD

Associate Director for Human Factors
Division of Medication Error Prevention and Analysis
Office of Surveillance and Epidemiology
CDER, FDA, Silver Spring, MD

David Nichols, MD

Associate Professor of Pediatrics
Pediatric Pulmonology
Seattle Children's Hospital
Medical Director
CF TDN Coordinating Center
Seattle Children's Research Institute
Seattle, WA

Peadar Noone, MD

Professor of Medicine
University of North Carolina
Chapel Hill, NC

Anne O'Donnell, MD

Professor of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Georgetown University Hospital
Washington DC

Thomas Smith, MD

Clinical Team Leader
DAIP, OAP
OND, CDER, FDA, Silver Spring, MD

Greg Tino, MD

Chief
Department of Medicine
Penn Presbyterian Medical Center
Associate Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

LaRee Tracy, PhD

Statistical Reviewer
Division of Biometrics IV
Office of Biostatistics, OTS
CDER, FDA, Silver Spring, MD

Donald VanDevanter, PhD

Adjunct Professor
Pediatrics
Case Western Reserve University School of Medicine

Pamela Zeitlin, MD

Silverstein Chair
Department of Pediatrics
Professor of Pediatrics
National Jewish Health
Denver, CO

Jasan Zimmerman

Patient Representative- Non-CF Bronchiectasis
Palo Alto, CA

Disclosures

Dr. Aksamit: Chair of US Bronchiectasis and NTM Research Registry

Research clinical study activity:

- US Bronchiectasis and NTM Research Registry
- Bayer, Cipro DPI, Global PI
- Aradigm/Grifols, Cipro liposomal
- Gilead, inhaled aztreonam
- Insmmed, inhaled liposomal amikacin

Dr. Alder: Stock in Bayer Pharmaceuticals

Dr. Barker: Receives grant support for a clinical research trial from Grifols. Currently a Consultant/Advisory Boards for the following: Grifols (Cipro liposomal).

Dr. Chalmers: Has received fees for consultancy related to the development of inhaled antibiotics from Aradigm Corporation, Grifols, Bayer Healthcare, Zambon and Insmmed. He chairs the European Bronchiectasis Registry which has received research funding from Aradigm, Grifols, Insmmed, Bayer Healthcare and Gilead.

Dr. Dhand: Has received remuneration from the following sources: GSK, Astra-Zeneca, UpToDate.

Dr. Flume: Has provided consultative services to the following: Bayer Healthcare AG, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Horizon Pharma, Insmmed, McKesson, Novartis, Proteostasis Therapeutics, and Vertex Pharmaceuticals, Inc. Dr. Flume has received grant support from the following: Bayer Healthcare AG, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Galapagos, Insmmed, National Institutes of Health, Novartis, Novoteris, Proteostasis Therapeutics, Sound Pharmaceuticals, Inc, and Vertex Pharmaceuticals, Inc.

Dr. Hamblett: As per Dr. Hamblett's role as Co-Executive Director of the Cystic Fibrosis Therapeutics Development Network Coordinating Center, her institution has received funds for

consulting activity provided for sponsors including: AbbVie Inc., Achaogen, AlgiPharma AS, Aridis Pharmaceuticals LLC, Bayer HealthCare AG, Catabasis, Celtaxsys, Corbus Pharmaceuticals, Covance, Inc., CURx Pharmaceuticals, Inc., Flatley Discovery Lab LLV, Gilead Sciences, Inc., Horizon Pharma, KaloBios, La Jolla Pharmaceutical, Laurent Pharmaceuticals, Life Science Strategies, Mylene Gencey, Nivalis Therapeutics, Inc., Novartis Pharmaceuticals Corp., ProQR Therapeutics B.V., Protalix Ltd., Proteostasis Therapeutics, Inc., Pulmatrix, Quintiles, Inc., Sanofi, Savara Pharmaceuticals, Synedgen, Inc., Teva Branded Pharmaceutical Products R&D, and Vertex Pharmaceuticals Incorporated.

Dr. Noone: Consultant/Ad panel: Bayer Inc, Grifols Inc., Electromed Inc. Sponsored trials: Parion Inc, Insemd Inc, Aradigm Inc., Gilead Inc, Pharmaxis Inc.

Dr. Nichols: Currently receives independent grant support from the NIH, CF Foundation, Gilead Sciences, and Grifols. Through his role at the TDN Coordinating Center, he consults with several Industry sponsors involved in CF clinical research.

Dr. O'Donnell: Principal Investigator/Grant support to Georgetown University (GU) for the following clinical trials

- Insmmed (new therapies for NTM and bronchiectasis)
- Bayer (inhaled antibiotic)
- Aradigm (inhaled antibiotic)
- Zambon (inhaled antibiotic)
- Foundation support to GU for Bronchiectasis Registry
 - COPD Foundation
- Consultant
 - Bayer (inhaled ciprofloxacin)
 - Grifols (inhaled ciprofloxacin)
 - Horizon (Inhaled levofloxacin)
 - Xellia Pharmaceuticals (antibiotic manufacture)
 - Electromed (Smart Vest)

Dr. Tino: Receives research grant support from the Bronchiectasis Research Registry/COPD Foundation. Dr. Tino has served on advisory boards/as a consultant for the following Pharma companies: Bayer, Grifols and Aradigm.

Dr. VanDevanter: Has served as a paid consultant to Abbvie, Affinium, Agile Biosciences, Albumedix, AN2, Aptalis, Aradigm, Baxter Healthcare, Catabasis, Chiesi USA, CF Foundation, Coleman, Concert, Corbus, CURx, Dannemiller, Debiopharm, Eloxx, Enbiotix, Flatley, Forest, Fortress, Genentech, Gilead Sciences, GlaxoSmithKline, Glycomimetics, Horizon, ICON, Inspire, Kalobios, Laurent, MedImmune, Merck, Mpex, NanoBio, Novartis, Novoclem, Ocularis, Orbimed, Protalix, Proteostasis, PTC Therapeutics, Pulmatrix, Pulmocide, Raptor, Savara, Synedgen, Targeted Genetics, Teva, Tripex, and Vertex.